EP0827395A1 - Topisch applizierbare mittel zur behandlung und prophylaxe der alopezie - Google Patents
Topisch applizierbare mittel zur behandlung und prophylaxe der alopezieInfo
- Publication number
- EP0827395A1 EP0827395A1 EP96919796A EP96919796A EP0827395A1 EP 0827395 A1 EP0827395 A1 EP 0827395A1 EP 96919796 A EP96919796 A EP 96919796A EP 96919796 A EP96919796 A EP 96919796A EP 0827395 A1 EP0827395 A1 EP 0827395A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vitamin
- liposome
- liposomes
- topically applicable
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- Topical agents for the treatment and prophylaxis of alopecia Topical agents for the treatment and prophylaxis of alopecia
- the invention relates to topically applicable agents for the treatment and prophylaxis of alopecia, which is characterized by a content of vitamin D analogs encapsulated in liposomes.
- vitamin D analogues can be used to treat various forms of alopecia.
- GB-A 2 260 903 and WO 93/00079 describe topically administrable compositions which contain vitamin D analogues in ointments, creams, gels or lotions. Since these previously known formulations, in particular if they additionally contain penetration-enhancing agents such as ethanol or propylene glycol, also have a systemic activity, they also develop undesirable side effects in addition to the desired therapeutic effect. In particular, they also influence calcium metabolism, which can lead to hypercalcemia and hypercalcuria.
- topically administrable agents according to the invention which contain vitamin D analogs encapsulated in liposomes, are extremely effective in treating various forms of alopecia, but in contrast to the previously known agents, undesirable systemic side effects are not observed in them.
- Vitamin D analogs which are suitable for the preparation of the agents according to the invention are, for example, calcitriol (l ⁇ , 25-dihydroyvitamin D3), calcifediol (25-hydroxyvitamin D3), calcipotriol (CAS-1128-00-9) and colecalciferol (Vitamin Ds) and the tacalcitol (CAS-57333-96-7).
- the vitamin D analogs mentioned in the abovementioned GB-A 2 260 903 and WO 93/00079 are also suitable for producing the agents according to the invention.
- the compounds described in WO 94/07853 are also suitable as suitable vitamin D analogs, such as, for example, the (5Z, 7E, 22E) - (1S, 3, 24R) -1, 3,24-trihydroxy-9, 10-secocholesta-5,7, 10 (19), 22-tetraen-25-carboxylic acid isopropyl ester.
- Suitable liposome-forming substances are in particular phospholipids, such as the sphingomyeline, the plasmalogens, the phosphatidylcholines, the phosphatidylethanolamines, the phosphatidylserines, the phosphatidylinosites and the cardiolipins, or else mixtures of these lipids (Dr. Otto-Albert Neumüller: Römpps Chemie-Lexikon; Franksche Verlag Stuttgart, Franksche Verlag Stuttgart (DE), 9th edition, 1991, 3383f) and mixtures of these phospholipids with cholesterol and / or charge carriers, such as, for example, stearylamine, stearic acid or diacetyl phosphate.
- phospholipids such as the sphingomyeline, the plasmalogens, the phosphatidylcholines, the phosphatidylethanolamines, the phosphatidylserines, the phosphatidylinosites and
- phospholipid or lipid mixture based on the aqueous phase, is usually used to prepare the liposome suspensions.
- Suitable mixtures can contain up to 60 percent by weight of cholesterol and up to 30 percent by weight of charge carriers.
- Ethanol, methanol, isopropanol, diethyl ether, acetone, chloroform and mixtures of these solvents are preferably used as solvents.
- the process is advantageously carried out under an inert gas atmosphere, such as nitrogen or argon, and the aqueous liposome solutions obtained are stabilized by adding antioxidants, such as sodium ascorbate, tocopherol or sodium bisulfite.
- aqueous liposome solutions can also contain additional active ingredients, such as bactericides, preservatives and / or buffer substances.
- the encapsulation of the vitamin D analogs in liposomes can be carried out under the same conditions as the previously known methods of this type (pharmacy in our time ü, 1982, 97-108; Pure Appl. Chem., 53, 1981, 2241-2254) .
- the encapsulation of the vitamin D analogs can take place both in multilamellar liposomes and in unilamellar liposomes.
- the active substance-containing liposome suspensions prepared in this way can be diluted with water if necessary and / or thickeners, such as, for example, hydroxyethyl cellulose, methyl cellulose, Aerosil® (Herseller Degussa AG, DE), Carbopol® (BFGoodrich Chem., USA) etc. can be added to make them spreadable To produce gels.
- thickeners such as, for example, hydroxyethyl cellulose, methyl cellulose, Aerosil® (Herseller Degussa AG, DE), Carbopol® (BFGoodrich Chem., USA) etc.
- the optimal concentration of active substance in the finished pharmaceutical preparations naturally depends on the type of active substance and the galenical preparation and must be determined in individual cases using the usual preliminary tests. As a rule, it will be sufficient to use pharmaceutical preparations which use 0.001 to 1 mg and preferably 0.005 to 0.1 mg of vitamin D analogs per g of preparation.
- the liposome suspension obtained contains liposomes with an average size of 112 nm.
- the phosphatidylcholine content is 9 mg per g; the content of encapsulated! Active ingredient is 0.1 mg per g.
- the solution is then evaporated to dryness in a 500 ml round-bottom flask on a rotary evaporator, a lipid film forming on the glass wall. This lipid film is removed with 98.9 g of double-distilled water.
- the suspension obtained is then subjected to high-pressure extrusion, as described in PCT / DE93 / 00997, using Nucleopore® membranes with a decreasing pore size of 5.0, 1.0, 0.4, 0.2, 0.1 and 0.05 ⁇ m is used.
- the liposome suspension obtained contains liposomes with an average size of 94 nm and otherwise has the same properties as the preparation described in Example 1.
- the liposome suspension thus obtained contains liposomes with an average size of 106 nm.
- the phosphatidylcholine content is 9.0 mg per g, the active ingredient content is 0.04 mg per g.
- the liposome suspension obtained contains liposomes with an average size of 220 nm.
- the phosphatidylcholine content is 10 mg per g; the content of encapsulated! Active ingredient is 0.2 mg per g.
- the liposome suspensions prepared according to Examples 1 and 3 are mixed with 0.18%
- the liposomes are still suspended in the aqueous phase. You are intact.
- the liposome suspensions prepared according to Examples 1 and 3 are freeze-dried.
- BHT 2,6-di tert-butyl-4-methylphenol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19519273 | 1995-05-22 | ||
DE19519273A DE19519273A1 (de) | 1995-05-22 | 1995-05-22 | Topisch applizierbare Mittel zur Behandlung und Prophylaxe der Alopezie |
PCT/EP1996/002195 WO1996037193A1 (de) | 1995-05-22 | 1996-05-22 | Topisch applizierbare mittel zur behandlung und prophylaxe der alopezie |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0827395A1 true EP0827395A1 (de) | 1998-03-11 |
Family
ID=7762883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96919796A Withdrawn EP0827395A1 (de) | 1995-05-22 | 1996-05-22 | Topisch applizierbare mittel zur behandlung und prophylaxe der alopezie |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0827395A1 (de) |
JP (1) | JPH11505262A (de) |
KR (1) | KR19990021864A (de) |
AU (1) | AU5819996A (de) |
CA (1) | CA2222061A1 (de) |
DE (1) | DE19519273A1 (de) |
WO (1) | WO1996037193A1 (de) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2262870C (en) * | 1996-04-04 | 2008-01-29 | Cilag Ag | Liposome-based topical vitamin d formulation |
US20030095937A1 (en) * | 2001-10-02 | 2003-05-22 | Koeffler H. Philip | Method for stimulating hair growth by administering vitamin D analogs |
US20030219465A1 (en) * | 2002-05-23 | 2003-11-27 | Suresh Kumar Gidwani | Composition for delivery of dithranol |
BR112012003372A2 (pt) | 2009-08-14 | 2019-09-24 | Berg Biosystems Llc | vitamina d3 e análogos da mesma para o tratamento de alopecia. |
US9375388B2 (en) | 2011-09-23 | 2016-06-28 | Indian Institute Of Technology, Bombay | Nanoparticle based cosmetic composition |
FR3017290B1 (fr) * | 2014-02-10 | 2017-05-12 | Dermaconcept Jmc | Composition pour lutter contre la chute des cheveux |
BR112021011023A2 (pt) | 2018-12-06 | 2021-08-31 | Lipicare Life Sciences Ltd. | Microemulsões de vitamina d e suas utilizações |
CN114126623A (zh) * | 2019-05-17 | 2022-03-01 | 宾夕法尼亚大学董事会 | 治疗肥胖和/或皮肤紊乱的方法和组合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116605A (en) * | 1989-03-09 | 1992-05-26 | Alt John P | Composition and skin treatment method therewith for mitigating acne and male-pattern baldness |
US5401731A (en) * | 1989-06-29 | 1995-03-28 | Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Productionsaktieselskab) | Vitamin D analogues |
GB8915770D0 (en) * | 1989-07-10 | 1989-08-31 | Leo Pharm Prod Ltd | Chemical compounds |
GB9007236D0 (en) * | 1990-03-30 | 1990-05-30 | Leo Pharm Prod Ltd | Chemical compounds |
GB9017890D0 (en) * | 1990-08-15 | 1990-09-26 | Leo Pharm Prod Ltd | Chemical compounds i |
ATE168367T1 (de) * | 1994-01-20 | 1998-08-15 | Duphar Int Res | Vitamin-d-derivate und verfahren zu deren herstellung |
-
1995
- 1995-05-22 DE DE19519273A patent/DE19519273A1/de not_active Withdrawn
-
1996
- 1996-05-22 WO PCT/EP1996/002195 patent/WO1996037193A1/de not_active Application Discontinuation
- 1996-05-22 EP EP96919796A patent/EP0827395A1/de not_active Withdrawn
- 1996-05-22 CA CA002222061A patent/CA2222061A1/en not_active Abandoned
- 1996-05-22 JP JP8535377A patent/JPH11505262A/ja active Pending
- 1996-05-22 AU AU58199/96A patent/AU5819996A/en not_active Abandoned
- 1996-05-22 KR KR1019970708338A patent/KR19990021864A/ko not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO9637193A1 * |
Also Published As
Publication number | Publication date |
---|---|
KR19990021864A (ko) | 1999-03-25 |
JPH11505262A (ja) | 1999-05-18 |
AU5819996A (en) | 1996-12-11 |
CA2222061A1 (en) | 1996-11-28 |
WO1996037193A1 (de) | 1996-11-28 |
DE19519273A1 (de) | 1996-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3785198T2 (de) | Liposomes praeparat und antibiotikum. | |
EP0224837B1 (de) | Hautwirksame Pharmaka mit Liposomen als Wirkstoffträger | |
DE3713494C2 (de) | ||
DE69717095T2 (de) | Topische vitamin d zusammensetzung auf liposomenbasis | |
DE69620473T2 (de) | Strahlungsschützende phospholipiden | |
US5166139A (en) | Complexes of saponins and their aglycons with phospholipids and pharmaceutical and cosmetic compositions containing them | |
CH652615A5 (de) | Verfahren zur herstellung eines gefriergetrockneten gemisches von potentiellen liposomen. | |
DE69029100T2 (de) | Verwendung von Ketoconazol und ein Retinoid zur Behandlung der Akne vulgaris | |
EP0451237B1 (de) | Pharmazeutische präparate | |
EP0011745A1 (de) | Kolloide wässrige Zusammensetzung für pharmazeutische Zwecke, und deren Herstellung | |
DE10255106A1 (de) | Liposomale Glucocorticoide | |
DE3713492C2 (de) | ||
KR20180131876A (ko) | 리포좀 기술을 이용한 안정화된 세라마이드 복합물 및 그 제조 방법 및 이를 함유하는 화장료 조성물 | |
DE69302897T2 (de) | Liposomale itraconazol formulierungen | |
DE69105767T2 (de) | Bilobalid-Phospholipid-Komplexe, ihre Anwendung und Zusammensetzungen enthaltend diese. | |
EP0707847A1 (de) | Ketoprofen Liposomen | |
WO1996037193A1 (de) | Topisch applizierbare mittel zur behandlung und prophylaxe der alopezie | |
DE3883246T2 (de) | Auf tocopherol basierte arzneimittelsysteme. | |
EP0464297A1 (de) | Neolignanderivatkomplexen mit Phospolipiden, deren Verwendung und sie enthaltende pharmazeutische und kosmetische Zusammensetzungen | |
DE69206913T2 (de) | Formulierungen zur Behandlung der vaginalen Trockenheit | |
DE19810999A1 (de) | Verwendung von Sphingosin, Sphingosin-1-Phosphat, Sphingosin-1-Phosphat-Derivaten und/oder deren Gemischen zur Behandlung von entzündlichen Hautkrankheiten | |
CA2416731C (en) | Liposomal formulation of clobetasol propionate | |
EP0571063A1 (de) | Pharmazeutische Präparate | |
EP0458924A1 (de) | Pharmazeutische präparate | |
DE68926473T2 (de) | Mittel zur Konservierung oder Wiederherstellung der gesunden Haut |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19971001 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ROESSLING, GEORG Inventor name: SACHSE, ANDREAS Inventor name: RIEDL, JUTTA Inventor name: LIPP, RALPH |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ROESSLING, GEORG Inventor name: SACHSE, ANDREAS Inventor name: RIEDL, JUTTA Inventor name: LIPP, RALPH |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 19990119 |